Immunotherapy data heralds new era of lung cancer treatment

A new era of lung cancer therapy is close to dawning, using drugs that can prevent tumour cells from evading the immune system, experts have said at the 4th European Lung Cancer Congress.For decades, scientists and doctors thought immunotherapy - treatments that harness the immune system to fight a disease - was of marginal benefit in lung cancer, says Jean-Charles Soria, Institute Gustave Roussy in Paris, France.However a new class of drugs known as "immunocheckpoint regulators" have shown huge potential, Soria says. New data on several of these drugs are presented at the conference.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Lung Cancer Source Type: news

Related Links:

Malignant pleural mesothelioma (MPM) is a rare tumor principally due to past exposure to asbestos, a carcinogenic natural mineral fiber that induces genomic and genetic alterations [1]. Lack of curative treatment due to resistance to anti-cancer therapies combined with tumor aggressiveness accounts for the poor prognosis associated to MPM. Despite the significant advances in oncotherapy, MPM is still a challenging cancer to treat [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Development of T-cell based immunotherapies for the treatment of various cancers has been challenged for decades by the lack of target antigens that are only expressed by cancer cells and not normal tissues. KK-LC-1 belongs to a family of tumor antigens known as cancer-testis antigens, which have restricted expression in immune-privileged germ cells and various cancers, and not in normal life-essential tissues. This makes KK-LC-1 an attractive target for T-cell based anti-cancer therapies.Inventors from the National Cancer Institute ’sExperimental Transplantation and Immunology Branch (NCI ETIB) have discovered two n...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
The number of elderly people with advanced lung cancer is increasing globally owing to the aging population and advances in cancer therapy [1]. More than 50% of patients diagnosed with lung cancer are aged>65 years, which is the lower limit for defining “elderly” in epidemiologic researches [2]. Non-small-cell lung cancer (NSCLC) accounts for 85% of all cases of lung cancer among both the elderly [3] and the adults. Although platinum-combination regimens including newer agents are the standard first-line chemotherapy for most patients with adva nced NSCLC, their use in elderly patients remains controversial [4].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research
Publication date: Available online 11 October 2018Source: The Annals of Thoracic SurgeryAuthor(s): Hideki Ujiie, Lili Ding, Rong Fan, Tatsuya Kato, Daiyoon Lee, Kosuke Fujino, Tomonari Kinoshita, Chang Young Lee, Thomas K. Waddell, Shaf Keshavjee, Brian C. Wilson, Gang Zheng, Juan Chen, Kazuhiro YasufukuAbstractBackgroundWe have developed ultra-small porphyrin-lipoprotein nanoparticles (
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Abstract BACKGROUND: We have developed ultra-small porphyrin-lipoprotein nanoparticles (
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Tags: Ann Thorac Surg Source Type: research
ConclusionsThis case series represents the first description of potential skeletal adverse effects related to immune checkpoint inhibitors. These findings are important for providers caring for patients who experience musculoskeletal symptoms and may merit additional evaluation.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research
Publication date: 1 December 2018Source: International Journal of Pharmaceutics, Volume 552, Issues 1–2Author(s): Tao Cui, Xiaohong Li, Yaqian Shu, Xianzhou Huang, Yan Wang, Wenli ZhangAbstractIn the present study, we have developed the robust nanoparticles (MGC-GNP/PTX), which are TAMs and tumor cells-dual recognizable, for targeting cancer therapy. Of great importance, the developed nano-platforms are glutathione (GSH)-activable, which means it remains structure intact under normal physiological condition and can be disrupted when exposed to certain concentration of GSH. As demonstrated by the drug release assay in...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
Publication date: Available online 3 October 2018Source: Chemico-Biological InteractionsAuthor(s): Pan Jiang, Hai Xu, Chuyue Xu, Aochang Chen, Lijun Chen, Ming Zhou, Ijaz ul Haq, Xiaoyue Wu, Zahula Mariyam, Qing FengAbstractLong non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisi...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Abstract Long non-coding RNAs (lncRNAs) have been identified to exert crucial roles in tumorigenesis and can serve as novel biomarkers for cancer therapy including lung cancer. Cisplatin is a first-line chemotherapeutic agent in non-small cell lung cancer (NSCLC), but the therapeutic effect is unsatisfactory, partly due to drug resistance. Emerging evidence showed that chemo-resistance is associated with acquisition of cancer stem cell (CSC)-like properties. Cisplatin resistance remains a major obstacle in the treatment of lung cancer, and its mechanism is still not fully elucidated. Meanwhile, CSCs have been invo...
Source: Chemico-Biological Interactions - Category: Molecular Biology Authors: Tags: Chem Biol Interact Source Type: research
Many lung cancer patients who undergo surgical resection ultimately require adjuvant therapy, yet current chemosensitivity models inadequately predict therapeutic response. We propose using a microdevice to test lung tumor responsiveness to simultaneous microdoses of 20 to 30 antineoplastic agents released directly into a tumor prior to operative resection. The 750 μm device is inserted into a tumor prior to surgery and remains in vivo until retrieval during surgical resection. Analysis of the cellular architecture surrounding the device using clinically relevant biomarkers and multiparameter immunohistochemistry yields...
Source: Journal of the American College of Surgeons - Category: Surgery Authors: Tags: Scientific poster presentations Source Type: research
More News: Cancer | Cancer & Oncology | Cancer Therapy | Conferences | Health | Lung Cancer | Politics